Table 1.
Patient parameters stratified by ex vivo dissection
| No EVD Group N=111 | EVD Group N=111 | P Value | |
|---|---|---|---|
| Patient-related Variables | |||
| Male, n (%) | 59 (53%) | 60 (54%) | 0.83 |
| Female, n (%) | 52 (47%) | 51 (46%) | |
| Age, years | 62±13.6 | 61±15.6 | 0.97 |
| Body mass Index [BMI] (kg/m2) | 26.9±5.3 | 26.6±4.8 | 0.81 |
| Tumor-related Variables | |||
| Histology, n (%): | |||
| Well-differentiated | 3 (3%) | 7 (6%) | |
| Moderately differentiated | 48 (43%) | 60 (54%) | 0.07 |
| Poorly differentiated | 60 (54%) | 44 (40%) | |
| Lauren classification, n (%): | |||
| Intestinal | 48 (43%) | 58 (52%) | |
| Mixed | 17 (15%) | 16 (14%) | 0.38 |
| Diffuse | 46 (42%) | 37 (34%) | |
| WHO classification, n (%) | |||
| Tubular | 65 (59%) | 57 (51%) | |
| Signet ring | 43 (39%) | 47 (42%) | 0.47 |
| Other/unknown | 4 (4%) | 7 (6%) | |
| Location, n (%): | |||
| Lower third | 51 (46%) | 46 (41%) | |
| Middle third | 34 (31%) | 29 (26%) | 0.32 |
| Upper third | 26 (23%) | 36 (33%) | |
| T status, n (%): | |||
| T0 | 6 (5%) | 7 (6%) | |
| T1a | 19 (17%) | 22 (20%) | |
| T1b | 20 (18%) | 19 (17%) | |
| T2 | 16 (14%) | 12 (11%) | 0.97 |
| T3 | 30 (27%) | 31 (28%) | |
| T4a | 18 (16%) | 19 (17%) | |
| T4b | 2 (2%) | 1 (1%) | |
| N status, n (%): | |||
| N0 | 64 (58%) | 63 (57%) | |
| N1 | 18 (16%) | 19 (17%) | 1.0 |
| N2 | 13 (12%) | 13 (12%) | |
| N3 | 16 (14%) | 16 (14%) | |
| Stage, n (%): | |||
| in situ | 6 (5%) | 6 (5%) | |
| I | 47 (43%) | 45 (41%) | |
| II | 29 (26%) | 31 (28%) | 0.98 |
| III | 28 (25%) | 27 (24%) | |
| IV | 1 (1%) | 2 (2%) | |
| Treatment-related Variables | |||
| Neoadjuvant Chemotherapy, n (%): | |||
| Yes | 50 (45%) | 61 (55%) | 0.18 |
| No | 61 (55%) | 50 (45%) | |
| Total/Subtotal Gastrectomy, n (%) | 44 (40%) | 44 (40%) | 1.0 |
| Distal Gastrectomy, n (%) | 67 (60%) | 67 (60%) | |
| Lymphadenectomy, n (%): | |||
| D1+ | 7 (6%) | 9 (8%) | 1.0 |
| D2 | 104 (94%) | 102 (92%) | |
WHO: World Health Organization